weekly_roundup

BioTechSign Daily Catalyst Roundup - November 11, 2026

Top BioTechSign catalyst names today: UCBNV, KURA, EIKN, ZBIO, CMPX, PBYI. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 11, 2026

Daily Biotech Catalyst Digest: November 11, 2026

UCBNV leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
UCBNVUCB SA100.0Aclinical activity 100%
KURAKura Oncology, Inc.86.6Apublication signal 100%, clinical activity 100%, short interest 70%
EIKNEikon Therapeutics, Inc.85.5Apublication signal 100%, clinical activity 100%, short interest 70%
ZBIOZenas BioPharma, Inc.83.2Aclinical activity 100%, short interest 90%, publication signal 35%
CMPXCompass Therapeutics, Inc.81.1Aclinical activity 92%, short interest 90%, publication signal 60%
PBYIPuma Biotechnology Inc79.7Bpublication signal 100%, clinical activity 100%, short interest 50%

Recent Grade-Change Queue

  • UCBNV (UCB SA) currently grades A with a 100.0/100 catalyst score. Main inputs: clinical activity 100%.
  • SNY (Sanofi SA) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
  • PBYI (Puma Biotechnology Inc) currently grades B with a 79.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
  • OPK (OPKO Health, Inc.) currently grades D with a 48.1/100 catalyst score. Main inputs: publication signal 100%, clinical activity 83%, short interest 50%.
  • EYPT (EyePoint, Inc.) currently grades D with a 49.9/100 catalyst score. Main inputs: short interest 70%, dilution risk 43%, publication signal 40%.
  • EXEL (Exelixis Inc) currently grades B with a 76.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
  • TARA (Protara Therapeutics, Inc. ) currently grades B with a 71.8/100 catalyst score. Main inputs: clinical activity 88%, short interest 50%, dilution risk 35%.
  • CMPX (Compass Therapeutics, Inc.) currently grades A with a 81.1/100 catalyst score. Main inputs: clinical activity 92%, short interest 90%, publication signal 60%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.